Skip to main content
HCPCS J9267 · Level II · Part B drug

J9267: paclitaxel, HCPCS Level II J code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for J9267

Billing unit
1 MG
Paclitaxel injection
ASP payment limit
$0.108
October 2026; -3.6% vs July 2026
Practitioner MUE
750
MAI 3
OPPS status
SI N
NCCI exposure
no PTP pairs
Coverage articles
1
5 states

TL;DR

HCPCS J9267 is the Level II code for Injection, paclitaxel, 1 mg, billed per 1 MG. The Medicare Part B ASP payment limit for October 2026 is $0.108 per billing unit, down 3.6% from July 2026. The practitioner MUE allows up to 750 units per date of service (MAI 3), so a full 750-unit day is $81.00 at the current limit. Under OPPS it carries status indicator N. With a 1 mg billing unit, a single administration can be hundreds of units; the unit count on the claim must equal the milligrams given, and rounding rules for partial units follow the contractor's guidance. The ASP crosswalk maps 32 NDCs to it, sold as Paclitaxel by Teva Parenteral Medicines, Inc., Northstar RxLLC, Heritage Pharmaceuticals Inc. 1 Medicare coverage article lists the code across 5 states, including A52450.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for J9267 at $0.108 per 1 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $0.112 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for J9267
QuarterPayment limitPerCoinsurance
October 2026$0.1081 MG20%
July 2026$0.1121 MG—
Source: CMS Medicare Part B Drug Payment Limit File. Commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 32 NDCs from 11 labelers to J9267. Report the NDC in the claim's drug segment and bill the number of J9267 units that equals the quantity administered divided by 1 MG; the last column gives units per full package.

NDCs that crosswalk to J9267
NDCDrug nameLabelerPackage sizeBilling units / package
00703-3213-01PaclitaxelTeva Parenteral Medicines, Inc.5 × 130
00703-3213-81PaclitaxelTeva Parenteral Medicines, Inc.5 × 130
00703-3216-01PaclitaxelTeva Parenteral Medicines, Inc.16.7 × 1100
00703-3216-81PaclitaxelTeva Parenteral Medicines, Inc.16.7 × 1100
00703-3217-01PaclitaxelTeva Parenteral Medicines, Inc.25 × 1150
00703-3218-01PaclitaxelTeva Parenteral Medicines, Inc.50 × 1300
00703-3218-81PaclitaxelTeva Parenteral Medicines, Inc.50 × 1300
16714-0137-01PaclitaxelNorthstar RxLLC50 × 1300
23155-0882-31PaclitaxelHeritage Pharmaceuticals Inc.5 × 130
23155-0883-31PaclitaxelHeritage Pharmaceuticals Inc.16.7 × 1100
23155-0884-31PaclitaxelHeritage Pharmaceuticals Inc.50 × 1300
25021-0255-05PaclitaxelSagent Pharmaceuticals5 × 130
25021-0255-17PaclitaxelSagent Pharmaceuticals16.7 × 1100
25021-0255-50PaclitaxelSagent Pharmaceuticals50 × 1300
61703-0015-04PaclitaxelPfizer Inc5 × 130
61703-0342-09PaclitaxelPfizer Inc5 × 130
61703-0342-22PaclitaxelPfizer Inc16.7 × 1100
61703-0342-50PaclitaxelPfizer Inc50 × 1300
62332-0620-05PaclitaxelAlembic Pharmaceuticals Inc.5 × 130
62332-0621-17PaclitaxelAlembic Pharmaceuticals Inc.16.7 × 1100
62332-0622-50PaclitaxelAlembic Pharmaceuticals Inc.50 × 1300
63323-0763-16PaclitaxelFreseniUS Kabi USA, LLC16.7 × 1100
63323-0763-50PaclitaxelFreseniUS Kabi USA, LLC50 × 1300
68001-0516-27PaclitaxelBluePoint Laboratories50 × 1300
68001-0705-27PaclitaxelBluepoint Laboratories50 × 1300
70860-0200-05PaclitaxelAthenex Pharmaceutical Division, LLC5 × 130
70860-0200-17PaclitaxelAthenex Pharmaceutical Division, LLC16.7 × 1100
70860-0200-50PaclitaxelAthenex Pharmaceutical Division, LLC50 × 1300
70860-0215-66PaclitaxelAthenex Pharmaceutical Division, LLC5 × 130
70860-0215-67PaclitaxelAthenex Pharmaceutical Division, LLC16.7 × 1100
70860-0215-68PaclitaxelAthenex Pharmaceutical Division, LLC50 × 1300
72205-0063-01PaclitaxelNovadoz Pharmaceuticals LLC50 × 1300

Medically Unlikely Edits (MUE)

CMS publishes 3 MUE values for J9267. For practitioners the limit is 750 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.

MUE values for J9267 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services7503 Date of Service Edit: ClinicalPrescribing Information
Facility outpatient hospital7503 Date of Service Edit: ClinicalPrescribing Information
DME supplier03 Date of Service Edit: ClinicalCMS Policy

MUE for J9267 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists J9267 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check J9267 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

J9267 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

1 current Medicare Administrative Contractor article lists J9267 in their HCPCS tables, covering 5 states. Each article carries the covered and non-covered ICD-10 codes that medical-necessity denials (CARC 50) are adjudicated against.

Billing and Coding Articles listing J9267
ArticleTitleContractor(s)StatesRelated LCD
A52450Billing and Coding: Paclitaxel (e.g., Taxol®/Abraxane ™)Wellpoint FederalCT IL MN NY WIL33394

Diagnoses Medicare contractors cover for J9267

One billing and coding article attaches a covered diagnosis list to J9267: 699 distinct ICD-10-CM codes in all. The 15 below come first by how many of those articles cover them, then in the contractor's own order. The claim line is checked against the list of the contractor that processes it, and a diagnosis outside that list is denied as not medically necessary (CARC 50).

First 15 covered ICD-10-CM codes for J9267
ICD-10-CMDescription (FY2027)Articles covering
C16.0Malignant neoplasm of cardia1 of 1
C16.1Malignant neoplasm of fundus of stomach1 of 1
C16.2Malignant neoplasm of body of stomach1 of 1
C16.3Malignant neoplasm of pyloric antrum1 of 1
C16.4Malignant neoplasm of pylorus1 of 1
C16.5Malignant neoplasm of lesser curvature of stomach, unspecified1 of 1
C16.6Malignant neoplasm of greater curvature of stomach, unspecified1 of 1
C16.8Malignant neoplasm of overlapping sites of stomach1 of 1
C17.0Malignant neoplasm of duodenum1 of 1
C17.1Malignant neoplasm of jejunum1 of 1
C17.2Malignant neoplasm of ileum1 of 1
C17.3Meckel's diverticulum, malignant1 of 1
C17.8Malignant neoplasm of overlapping sites of small intestine1 of 1
C17.9Malignant neoplasm of small intestine, unspecified1 of 1
C21.0Malignant neoplasm of anus, unspecified1 of 1
684 more codes are in the full lists linked below.

Contractors split an article's diagnoses into numbered groups and say in each group's instructions which procedure codes it supports. Only the groups that apply to J9267 are counted here. The full list opens on the policy page with every group, the non-covered codes and the instructions.

Covered diagnosis lists that apply to J9267, by article
ArticleContractorGroups that applyCovered codes for J9267Full list
A52450Wellpoint Federalone list for every code in the article699On LCD L33394

Local coverage policies that list J9267

1 active Local Coverage Determination lists J9267 in the policy or in its billing and coding article. Each applies only in its contractor's jurisdiction; check the one for the state where the drug is administered.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, J9267 carries status indicator N. Status N means payment is packaged into the associated procedure and no separate OPPS payment is made.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), J9267 carries payment indicator N1, which CMS defines as "Packaged service/item; no separate payment made". An N1 drug is packaged in the ASC: the facility receives no separate payment because the surgical procedure's rate already includes it.

Common denials for J9267 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for J9267

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS J9267

What does HCPCS code J9267 describe?

J9267 is defined by CMS as "Injection, paclitaxel, 1 mg". Each billing unit represents 1 MG, so the units reported on the claim must equal the dose administered divided by that unit.

Is J9267 a CPT code?

No. J9267 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as paclitaxel; CPT codes are five-character codes maintained by the AMA. On a Part B claim J9267 reports the drug itself in 1 mg units, and the administration is billed on its own line.

What is the Medicare reimbursement for J9267 in October 2026?

The ASP-based payment limit is $0.108 per 1 MG, with 20% beneficiary coinsurance. The July 2026 limit was $0.112. Commercial payers use their own fee schedules.

How many units of J9267 can be billed per day?

The practitioner Medically Unlikely Edit is 750 units per date of service with adjudication indicator 3 (Date of Service Edit: Clinical). MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "Prescribing Information" as the rationale.

Which NDCs map to J9267?

The October 2026 ASP crosswalk lists 32 NDCs from 11 labelers: Paclitaxel (Teva Parenteral Medicines, Inc.); Paclitaxel (Northstar RxLLC); Paclitaxel (Heritage Pharmaceuticals Inc.); Paclitaxel (Sagent Pharmaceuticals). For example NDC 00703-3213-01 (package size 5) equals 30 billing units of J9267.

Does J9267 have NCCI bundling edits?

No active practitioner PTP pairs list J9267 as a column-1 or column-2 code in the v323r0 release.

Which Medicare coverage articles mention J9267?

1 current Billing and Coding Article in the Medicare Coverage Database lists J9267, covering 5 states: A52450 (Billing and Coding: Paclitaxel (e.g., Taxol®/Abraxane ™)).

What diagnosis codes support J9267?

One Medicare billing and coding article lists 699 covered ICD-10-CM codes for J9267, for example C16.0 (Malignant neoplasm of cardia); C16.1 (Malignant neoplasm of fundus of stomach); C16.2 (Malignant neoplasm of body of stomach); C16.3 (Malignant neoplasm of pyloric antrum); C16.4 (Malignant neoplasm of pylorus). Each contractor's list applies only in its own jurisdiction, so the claim must carry a code from the article of the contractor that processes it.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.